GlassScriptPhysician profile
Richard S Izewski
NPI 1306930177
$9,904.03
in general payments reported to CMS, 2019-2025
35 companies · $951 in 2025
The $951 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $290 · 2021: $4,872 · 2022: $716 · 2023: $964 · 2024: $671 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $4,064.00 | 2021 | |
| Novo Nordisk INC | $1,065.89 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $880.81 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $626.40 | 2019-2024 | Xarelto |
| Pfizer INC. | $589.59 | 2020-2025 | |
| Amgen INC. | $327.29 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $310.39 | 2019-2024 | |
| Lilly USA, LLC | $308.90 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $187.69 | 2019-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $187.43 | 2019-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $166.53 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $153.63 | 2021-2022 | |
| Gilead Sciences, INC. | $144.92 | 2023-2025 | Livdelzi, Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $132.78 | 2019-2023 | Eliquis |
| Melinta Therapeutics, LLC | $118.71 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.56 | 2019-2023 | |
| Axsome Therapeutics, INC. | $61.38 | 2025 | Symbravo |
| Mannkind Corporation | $59.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $59.27 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $48.55 | 2022-2024 | Farxiga |
| Lundbeck LLC | $47.30 | 2023 | Rexulti |
| Abbott Laboratories | $40.57 | 2023-2024 | Freestyle Libre 3 |
| Lexicon Pharmaceuticals, INC. | $27.36 | 2024 | |
| Biogen, INC. | $24.42 | 2025 | Skyclarys |
| Sanofi-Aventis U.S. LLC | $23.27 | 2021 | |
| Ibsa Pharma INC. | $23.24 | 2021 | |
| Astellas Pharma US INC | $20.89 | 2022 | |
| Viatris Specialty LLC | $19.55 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $19.25 | 2024 | Nexletol |
| Eisai INC. | $18.96 | 2024 | |
| Sumitomo Pharma America, INC. | $18.46 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.56 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $15.39 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.33 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Izewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.